Apr 02, 2024 7:30am EDT Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Mar 26, 2024 7:53am EDT FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients
Jan 08, 2024 7:00am EST Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine
Nov 08, 2023 5:30pm EST Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million
Oct 17, 2023 9:15am EDT Medexus Announces Full Exercise and Closing of Over-Allotment Option in Bought-Deal Public Offering
